Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): A review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women

Drugs

Volumn 70, Issue 18, 2010, Pages 2449-2474

  McCormack, Paul L ^a   Joura, Elmar A ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adis Drug Evaluations; Cervical cancer, prevention; Genital warts, prevention; Human papillomavirus infections; Human papillomavirus vaccine recombinant quadrivalent, general

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; SILGARD; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANAPHYLAXIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BRONCHOSPASM; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENITAL TRACT CANCER; GUILLAIN BARRE SYNDROME; HEADACHE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; HYPERSENSITIVITY; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JOINT MOBILITY; LIMB PAIN; MOTOR NEURON DISEASE; MYALGIA; NAUSEA; NONHUMAN; PANCREATITIS; PRECANCER; RASH; RHINITIS; SIDE EFFECT; SYNCOPE; TENSION HEADACHE; ULCERATIVE COLITIS; URTICARIA; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VAGINA BLEEDING; VAGINA CANCER; VERTIGO; VIRUS PARTICLE; VULVA CANCER;

ADOLESCENT; ADULT; AGED; ANIMALS; CHILD; CONDYLOMATA ACUMINATA; FEMALE; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; YOUNG ADULT;

ANIMALIA; HUMAN PAPILLOMAVIRUS; MIRIDAE;

EID: 78649933032     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11204920-000000000-00000     Document Type: Article

References (89)

1. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006 Nov; 118 (5): 2135-45.
2. Collins S, Mazloomzadeh S, Winter H, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002 Jan; 109 (1): 96-8.
3. Winer RL, Lee SK, Hughes JP, et al. Genital human pa- pillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003 Feb 1; 157 (3): 218-26.
4. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005 Mar 1; 191 (5): 731-8.
5. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 Aug 20; 111 (2): 278-85.
6. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006 Aug 31; 24 Suppl. 3: S3-11-25.
7. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004 Dec; 31 (6): 744-54.
8. Kreimer AR, Clifford GM, Boyle P, et al. Human papillo- mavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Bio-markers Prev 2005 Feb; 14 (2): 467-75.
9. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006 Aug 31; 24 Suppl. 3: S3-35-41
10. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009 Mar 15; 199 (6): 805-14.
11. Stanley M. Prophylactic HPV vaccines. J Clin Pathol 2007 Sep; 60 (9): 961-5.
12. GlaxoSmithKline. Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant): US prescribing information [online]. Available from URL: http://us.gsk.com/ products/assets/us-cervarix.pdf [Accessed 2010 Nov 9].
13. European Medicines Agency. Gardasil (human papilloma- virus vaccine [types 6, 11, 16, 18] recombinant, absorbed): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/Humans/ EPAR/gardasil/gardasil.htm [Accessed 2010 Nov 9].
14. Merck & Co. Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant]: US prescribing information [online]. Available from URL: http:// www.merck.com/product/usa/pi-circulars/g/gardasil/ gar dasil-pi.pdf [Accessed 2010 Nov 9].
15. Villa LL, Costa RL, Petta CA, et al. Prophylactic quad- rivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005 May; 6 (5): 271-8.
16. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 Dec 4; 95 (11): 1459-66.
17. Villa LL, Ault KA, Giuliano AR, et al. Immunologic re- sponses following administration of a vaccine targeting human papillomavirus types 6, 11,16, and 18. Vaccine 2006 Jul 7; 24 (27-28): 5571-83.
18. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007 Jun 21; 25 (26): 4931-9.
19. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007 Jul 31; 3 (4): 109-15.
20. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 May 10; 356 (19): 1928-43.
21. Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody le- vels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008 Dec 9; 26 (52): 6844-51.
22. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 May 10; 356 (19): 1915-27.
23. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008 Jan 30; 26 (5): 686-96.
24. Garland SM, Steben M, Hernandez-Avila M, et al. Non- inferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 2007 Jun; 14 (6): 792-5.
25. Munoz N, Manalastas Jr R, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009 Jun 6; 373 (9679): 1949-57.
26. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11,16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007 Mar; 26 (3): 201-9.
27. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009 Oct; 5 (10): 705-19.
28. Ruiz W, McClements WL, Jansen KU, et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines 2005 Apr 20; 3 (1): 2-12.
29. Dias D, Van Doren J, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005 Aug; 12 (8): 959-69.
30. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 2007 Oct 15; 196 (8): 1153-62.
31. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 Nov 21; 347 (21): 1645-51.
32. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J 2010 Apr; 29 (4): 314-8.
33. Reisinger KS, Block SL, Collins-Ogle M, et al. Safety, tol- erability, and immunogenicity of Gardasil given concomitantly with Menactra and Adacel. Pediatrics 2010 Jun; 125 (6): 1142-51.
34. Arguedas A, Soley C, Loaiza C, et al. Safety and immuno- genicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010 Apr 19; 28 (18): 3171-9.
35. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled anal- ysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2009 Oct; 2 (10): 868-78.
36. Majewski S, Bosch FX, Dillner J, et al. The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol 2009 Oct; 23 (10): 1147-55.
37. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009 Apr 1; 199 (7): 926-35.
38. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009 Apr 1; 199 (7): 936-44.
39. Barr E, Gause CK, Bautista OM, et al. Impact of a pro- phylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women. Am J Obstet Gynecol 2008 Mar; 198 (3): 261.e1-11.
40. FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007 Nov 15; 196 (10): 1438-46.
41. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer 2008 Mar 15; 122 (6): 1311-8.
42. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009 Oct 14; 5 (10): 696-704.
43. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010 Mar 3; 102 (5): 325-39.
44. Ault KA, FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007 Jun 2; 369 (9576): 1861-8.
45. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007 May 19; 369 (9574): 1693-702.
46. European Medicines Agency. Assessment report: Gardasil, type II variation, scientific discussion [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/ EPAR/gardasil/Gardasil-H-703-II-20-AR. pdf [Accessed 2010 Nov 9].
47. Joura EA, Garland SM, Paavonen J, et al. Impact of Gardasil® in women who have undergone definitive therapy [abstract no. SS 4-3]. European Research Organisation on Genital Infection and Neoplasia (EUROGIN 2010): 9th International Multidisciplinary Congress; 2010 Feb 17-20; Monte Carlo.
48. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human pa- pillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J 2010 Feb; 29 (2): 95-101.
49. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus re-combinant vaccine. JAMA 2009 Aug 19; 302 (7): 750-7.
50. Borja-Hart NL, Benavides S, Christensen C. Human pa- pillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System. Ann Pharmacother 2009 Feb; 43 (2): 356-9.
51. Brotherton JM, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ 2008 Sep 9; 179 (6): 525-33.
52. Kang LW, Crawford N, Tang ML, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ 2008; 337: 1392-6.
53. Annemans L, Remy V, Oyee J, et al. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27 (3): 231-45.
54. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillo-mavirus vaccine (6/11/16/18) in the UK. BJOG 2008 Jul; 115 (8): 947-56.
55. Kulasingam SL, Benard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. Cost Eff Resour Alloc 2008; 6: 4.
56. Bergeron C, Largeron N, McAllister R, et al. Cost- effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008 Winter; 24 (1): 10-9.
57. Insinga RP, Dasbach EJ, Elbasha EH, et al. Cost-effective- ness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007 Dec 21; 26 (1): 128-39.
58. Mennini FS, Rossi PG, Palazzo F, et al. Health and eco- nomic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009 Feb; 112 (2): 370-6.
59. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008 Aug 21; 359 (8): 821-32.
60. Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008; 24 (5): 1473-83.
61. Brisson M, Van de Velde N, De Wals P, et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007 Jul 20; 25 (29): 5399-408.
62. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007 Jan; 13 (1): 28-41.
63. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost- effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008 Feb; 14 (2): 244-51.
64. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010 Apr; 20 (2): 213-9.
65. Dasbach EJ, Nagy L, Brandtmuller A, et al. The cost effec- tiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010 Mar; 13 (1): 110-8.
66. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010 Apr; 26 (2): 183-91.
67. Dasbach EJ, Larger on N, Elbasha EH. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Phar-macoecon Outcomes Res 2008 Oct; 8 (5): 491-500.
68. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008 Aug 9; 337 (7665): 331-5.
69. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009 Dec; 114 (6): 1179-88.
70. Dana A, Buchanan KM, Goss MA, et al. Pregnancy out- comes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009 Dec; 114 (6): 1170-8.
71. Advisory Committee on Cancer Prevention. Recommend- ations on cancer screening in the European, Union [online]. Available from URL, http://ec.europa.eu/health/ph-de terminants/genetics/cancer-screening-en.pdf, [Accessed 2010 Nov 9].
72. International Agency for Research on Cancer. GLOBOCAN, 2008 database [online]. Available from URL:, http://glo bocan.iarc.fr/ [Accessed 2010 Nov 9].
73. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009 Sep 18; 27 (41): 5612-9.
74. World Health Organization. Human papillomavirus (HPV) vaccine background paper. 2008, Sep [online]. Available from URL: http://www.who.int/immunization/ documents/ HPVBGpaper05032009.pdf [Accessed 2010 Nov 9].
75. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) viruslike particle (VLP) type 16 prophylactic vaccine. Vaccine 2007 May 22; 25 (21): 4324-33.
76. Bonanni P, Cohet C, Kjaer SK, et al. A summary of the post- licensure surveillance initiatives for Gardasil/Silgard®. Vaccine 2010 Jul 5; 28 (30): 4719-30.
77. Markowitz LE, Hariri S, Unger ER, et al. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010 Jul 5; 28 (30): 4731-7.
78. World Health Organization. WHO position on HPV vac- cines. Vaccine 2009; 27: 7236-7.
79. European Centre for Disease Prevention and Control. Gui- dance for the introduction of HPV vaccines in EU countries. 2008 Jan, 1-57 [online]. Available from URL: http:// www.ecdc.europa.eu/en/publications/Publications/0801- GUI-Introduction-of-HPV-Vaccines-in-EU.pdf [Accessed 2010 Nov 9].
80. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007 Mar 23; 56 (RR-2): 1-24.
81. Di Giuseppe G, Abbate R, Liguori G, et al. Human pa- pillomavirus and vaccination: knowledge, attitudes, and behavioural intention in adolescents and young women in Italy. Br J Cancer 2008 Jul 22; 99 (2): 225-9.
82. Kwan TTC, Chan KKL, Yip AMW, et al. Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect 2008 Jun; 84 (3): 227-32.
83. Ishibashi KL, Koopmans J, Curlin FA, et al. Paediatricians' attitudes and practices towards HPV vaccination. Acta Paediatr 2008; 97 (11): 1550-6.
84. Katz ML, Reiter PL, Heaner S, et al. Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine 2009 Jun 19; 27 (30): 3945-52.
85. Lenselink CH, Gerrits MMJG, Melchers WJG, et al. Par- ental acceptance of human papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol 2008 Mar; 137 (1): 103-7.
86. European Cervical Cancer Association. HPV vaccination across Europe [online]. Available from URL: http:// www.ecca.info/fileadmin/user-upload/HPV- Vaccination/ ECCA-HPV-Vaccination-April-2009.pdf [Accessed 2010 Nov 9].
87. National Health Services Scotland Information Services Division. HPV immunization uptake statistics [online]. Available from URL: http://www.isdscotland.org/isd/6153. html [Accessed 2010 Nov 9].
88. Centers for Disease Control and Prevention. US National Immunization Survey: estimated vaccination coverage with selected vaccines among adolescents aged 13-17 years [online]. Available from URL: http://www2a.cdc.gov/nip/ coverage/nisteen/nis-iap.asp?fmt=v&rpt=tab01-iap&qtr=Q1/ 2008-Q4/2008 [Accessed 2010 Nov 9].
89. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. Epub 2010 Nov 9